New sphingolipid strategy may help beat drug‑resistant tuberculosis

Tuberculosis remains a major lung infection, and recent studies have pointed to a surprising contributor to disease outcome: low levels of sphingolipids in the lung. In earlier work, investigators showed that Sphingosine −1 phosphate (a central Sphingolipid metabolite) can help the host limit Mycobacterium tuberculosis burden by tweaking M1 retuning of infected macrophages, but allergic and autoimmune manifestations associated with Sphingosine −1 phosphate have prevented its use as an anti-tubercular drug. Faced with that limitation, and with a growing need for new host-directed anti-tubercular therapies, Hridayesh Prakash and his team turned to a different idea: instead of giving Sphingosine −1 phosphate itself, could they boost sphingolipid production in the host through de novo biosynthesis? To test this, the researchers evaluated their patented compounds ATLS2021 and PA as tools to raise sphingolipid levels and thereby help the immune system control infection. Their work moves the focus from directly killing bacteria to strengthening host defenses by restoring a biochemical pathway that appears important in controlling tuberculosis in the lung.

The team tested ATLS2021 and PA in multiple experimental models and with clinical isolates. Their results showed that ATLS2021 was effective at controlling survival of both wild type and MDR (multidrug-resistant) strains of Mycobacterium tuberculosis in the systems they examined. Mechanistically, the study found an influence of ATLS2021 on NO mediated killing of mycobacteria, pointing to nitric-oxide–dependent bacterial clearance as one possible anti-mycobacterial mechanism of ATLS2021. The compound also lowered the IC50 value of Rifampicin for both wild-type and MDR TB by sensitizing an MDR clinical isolate to Rifampicin-mediated killing, suggesting ATLS2021 can make existing antibiotics more effective. ATLS2021 induced immunogenic responses in blood derived CD14+ macrophages from both healthy donors and an MDR-TB patient, indicating immune adjuvant potential. Real time PCR data showed that ATLS2021 enhanced the expression of almost all key enzymes involved in the Sphingolipid biosynthesis pathways in CD14 positive monocytes from healthy donors and MDR TB patients, supporting the idea that the drug boosts de novo sphingolipid production.

Taken together, these findings advocate a host-directed approach centered on boosting sphingolipid biosynthesis as a possible strategy against acute and drug‑resistant tuberculosis. By increasing the host’s sphingolipid machinery, ATLS2021 appears to both stimulate immune cells (CD14+ macrophages) and promote NO mediated killing of Mycobacterium tuberculosis, while also lowering the antibiotic dose needed for Rifampicin to be effective against resistant isolates. Because Sphingosine −1 phosphate itself carries risks of allergic and autoimmune effects, a therapy that elevates sphingolipids through the body’s own biosynthetic pathways—such as with ATLS2021 or PA—could offer a safer, indirect route to harness the same biology. The authors present these data as a potential immunogenic intervention against TB, noting that ATLS2021 has both direct effects on bacterial survival in models and measurable impacts on host gene expression related to sphingolipid production. Further work will be needed to define safety, dosing, and clinical benefit, but the study establishes a plausible new angle for tackling MDR tuberculosis.